Lifecore Biomedical AI Stock Analysis
Want to see LFCR full AI Analyst Report?
Lifecore Biomedical (LFCR) AI Stock Analysis
Lifecore Biomedical
(NASDAQ:LFCR)
The score is held down primarily by weak financial performance—ongoing losses and a strained balance sheet with negative equity—despite improved 2026 cash flow. Technicals add support with the price above key moving averages and positive momentum. Corporate events (take-private deal progress and the long-term Alcon agreement) provide meaningful near-term support, while valuation remains hard to justify on earnings given the negative P/E.
Lifecore Biomedical (LFCR) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $243.36M
- Dividend Yield
- ―
- Average Volume (3M)
- 403.05K
- Price to Earnings (P/E)
- -3.4
- Beta (1Y)
- 1.77
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 382
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Lifecore Biomedical Business Overview & Revenue Model
Company Description
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services i...
How the Company Makes Money
Lifecore primarily makes money by providing fee-for-service CDMO work to biopharmaceutical and biotechnology customers. Its core revenue stream is manufacturing services for injectable drug products, particularly sterile fill-finish, where customers...
Lifecore Biomedical Earnings Call Summary
Balanced/Neutral. The call highlighted substantial strategic and operational progress — a growing late-stage pipeline, meaningful new business momentum (13 wins in 12 months), successful regulatory audits (including PMDA), sustained SG&A reductions (cumulative $16.2M) and improved liquidity ($38.8M) — and management reaffirmed 2026 guidance. However, near-term financials showed meaningful declines: Q2 revenue down 6.2% YoY and six-month revenue down 19.9%, widened net losses (Q2 and 6-month), and a sizable drop in 6-month adjusted EBITDA (~34.5%). Management expects a back-half recovery and a 2027–2028 volume inflection with a major customer's committed demand ramp, but execution and timing risks remain. Overall, positives around pipeline, wins, quality and cost discipline are offset by short-term revenue and profitability headwinds, yielding a neutral outlook.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Lifecore reaffirmed 2026 guidance of $120–125 million in revenue and $20.5–25.0 million in adjusted EBITDA, noting H2 midpoint expectations of roughly $65 million in revenue and $13 million in adjusted EBITDA with a Q4-weighted back half and a step-up in CDMO/aseptic revenue; Q2 results were $34.2M revenue, $12.1M gross profit, $8.0M SG&A, $8.6M adjusted EBITDA and a $6.2M net loss ($0.19/share), while the six‑month totals were $57.4M revenue, $16.5M gross profit, $15.9M SG&A, $9.6M adjusted EBITDA and a $21.1M net loss ($0.61/share). Liquidity at quarter end was ~$38.8M (cash $17.2M + revolver availability $21.6M), free cash flow for the year is targeted at ~$7–10M, and the company has achieved cumulative SG&A/R&D savings of $16.2M since late‑2024 with SG&A expected to trend to about $6M/quarter (ex‑one‑time items) in the back half. Looking to the mid/long term, Lifecore reiterated a 12% revenue CAGR to 2029, a >25% adjusted EBITDA margin target by 2029, ~60% installed capacity utilization by 2029, and specific program/demand metrics including a doubling of committed fill/finish demand beginning in 2027 (and >200% increase in 2028 vs 2026), 11 development programs potentially commercializing by end‑2028, and recent business development wins (6 in Q2, 9 YTD, 13 LTM) with >60% of competed opportunities being late‑stage or site transfers.
Lifecore Biomedical Financial Statement Overview
Summary
Financials are stressed overall: revenue is roughly flat to down and profitability is weak with persistent losses (2026 EBIT margin ~-1.0% and net margin ~-23.8%). The balance sheet is a major risk with high leverage and negative equity in 2026, limiting flexibility. Cash flow is the main bright spot with positive 2026 operating cash flow (~$12.6M) and free cash flow (~$6.2M), but the historical trend is inconsistent.
Income Statement
34NegativeBalance Sheet
22NegativeCash Flow
45Neutral| Breakdown | TTM | Dec 2025 | May 2025 | May 2024 | Aug 2023 | May 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 91.53M | 129.46M | 128.87M | 128.26M | 103.27M | 111.27M |
| Gross Profit | 28.61M | 40.61M | 40.30M | 41.85M | 27.98M | 39.07M |
| EBITDA | 2.99M | 5.98M | -8.81M | 35.56M | -33.17M | 12.84M |
| Net Income | -27.29M | -30.79M | -38.72M | 12.01M | -99.56M | -116.72M |
Balance Sheet | ||||||
| Total Assets | 232.18M | 232.18M | 239.34M | 253.96M | 253.54M | 274.70M |
| Cash, Cash Equivalents and Short-Term Investments | 17.47M | 17.47M | 8.27M | 8.46M | 19.09M | 991.00K |
| Total Debt | 142.61M | 142.61M | 130.82M | 133.57M | 112.62M | 247.78M |
| Total Liabilities | 246.38M | 246.38M | 238.01M | 242.65M | 257.77M | 186.88M |
| Stockholders Equity | -14.20M | -14.20M | 1.34M | 11.31M | -4.23M | 87.82M |
Cash Flow | ||||||
| Free Cash Flow | -106.28K | 6.23M | -13.62M | -18.14M | -38.92M | -52.53M |
| Operating Cash Flow | 3.05M | 12.57M | -206.00K | 257.00K | -17.44M | -22.59M |
| Investing Cash Flow | 13.99M | -1.63M | -6.42M | -18.39M | -4.81M | 79.96M |
| Financing Cash Flow | -6.52M | -1.11M | 6.42M | 7.51M | 39.70M | -57.02M |
Lifecore Biomedical Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFCR, the sentiment is Positive. The current price of 6.42 is above the 20-day moving average (MA) of 6.41, above the 50-day MA of 5.79, and above the 200-day MA of 5.41, indicating a bullish trend. The MACD of 0.12 indicates Positive momentum. The RSI at 63.79 is Neutral, neither overbought nor oversold. The STOCH value of 52.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LFCR.
Lifecore Biomedical Risk Analysis
Lifecore Biomedical disclosed 30 risk factors in its most recent earnings report. Lifecore Biomedical reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksLifecore Biomedical Peers Comparison
Overall Rating
IRWD72Outperform
CPIX53Neutral
LFCR52Neutral
DERM50Neutral
BIOA41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 72Outperform | $799.61M | 5.33 | -93.40% | ― | 18.09% | 403.76% | |
| 53Neutral | $88.10M | 1.28 | 202.58% | 23.57% | -39.11% | -241.27% | |
| 52Neutral | $243.36M | -3.40 | 381.59% | ― | ― | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $122.21M | -23.29 | -16.07% | ― | 17.03% | 49.40% | |
| 41Neutral | $255.07M | -2.18 | -31.42% | ― | 45.33% | -20.81% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| LFCR | Lifecore Biomedical, Inc. | 6.42 | -1.48 | -18.73% | |
| IRWD | Ironwood Pharmaceuticals | 4.83 | 1.70 | 54.31% | |
| CPIX | Cumberland Pharmaceuticals Inc. | 5.88 | 4.41 | 299.19% | |
| SXTC | China Sxt Pharmaceuticals | 3.00 | -1619997.00 | -100.00% | |
| DERM | Journey Medical Corporation | 4.33 | -3.36 | -43.69% | |
| BIOA | BioAge Labs, Inc. | 5.55 | -2.76 | -33.21% |
Lifecore Biomedical Corporate Events
Lifecore Biomedical Receives Antitrust Clearance for Proposed Merger
PositiveOn September 27, 2026, Lifecore Biomedical entered into an agreement with Lifecore Inc. and Hazel Merger Sub to merge Hazel Merger Sub with and into the company, with Lifecore Biomedical surviving as a wholly owned subsidiary of Lifecore Inc. On Nove...
Lifecore Sets Record Date for Merger Vote
NeutralOn September 27, 2026, Lifecore Biomedical, Inc. entered into a Merger Agreement with Lifecore Inc. and Hazel Merger Sub, Inc., and on October 16, 2026, its board set November 4, 2026, as the record date for a special stockholder meeting to vote on a...
Lifecore Biomedical Extends Key Manufacturing Pact with Alcon
PositiveOn September 24, 2026, Lifecore Biomedical entered into a Third Amendment to its Amended and Restated Contract Manufacturing Agreement with Alcon Research, effective November 1, 2026, extending the agreement’s initial term from December 31, 2031 to D...
Lifecore Biomedical to Go Private in Webster Buyout
PositiveOn September 27–28, 2026, Lifecore Biomedical agreed to be acquired by an affiliate of private equity firm Webster Equity Partners in a deal valued at up to $663.7 million, assuming full achievement of performance milestones. The transaction, unanimo...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026
